GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

(MENAFN) British medicine producer GSK on Monday noted that it is going to purchase US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston-originated biotechnology company is ...

GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...